Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Pharmacokinetics and Excretion of [¹⁴C]Etelcalcetide (AMG 416) in Patients With End Stage Renal Disease (ESRD) Receiving Dialysis
Phase 1
Completed
- Conditions
- Secondary Hyperparathyroidism in Patients With ESRD on Hemodialysis
- Interventions
- Drug: [¹⁴C]Etelcalcetide
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 6
- Registration Number
- NCT02054572
- Locations
- 🇺🇸
DaVita Clinical Research Center, Minneapolis, Minnesota, United States
Bioequivalence Study of Denosumab CP4 Drug Product and Commercially Available Denosumab CP2 Drug Product
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2017-12-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 146
- Registration Number
- NCT02053753
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease
Phase 2
Completed
- Conditions
- Inherited Mitochondrial Disease, Including Leigh Syndrome
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 36
- Registration Number
- NCT02023866
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of California at San Diego (UCSD), San Diego, California, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- First Posted Date
- 2013-12-20
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 294
- Registration Number
- NCT02016716
- Locations
- 🇵🇱
Research Site, Wroclaw, Poland
Single-arm Trial to Evaluate the Biodistribution and Shedding of Talimogene Laherparepvec
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2019-11-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT02014441
- Locations
- 🇨🇦
Research Site, Montreal, Quebec, Canada
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 3
Terminated
- Conditions
- Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- Interventions
- Drug: Standard of Care Chemotherapy
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 405
- Registration Number
- NCT02013167
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- First Posted Date
- 2013-12-13
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 310
- Registration Number
- NCT02010931
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Historical Data Analysis of Hematological Remission and Survival in Adults With R/R Acute Lymphoblastic Leukemia
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Other: Not applicable - observational study
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2373
- Registration Number
- NCT02003612
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia
Phase 2
Completed
- Conditions
- Relapsed/Refractory Philadelphia Positive B-precursor ALL
- Interventions
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 45
- Registration Number
- NCT02000427
- Locations
- 🇬🇧
Research Site, Sutton, United Kingdom
A Study of Oprozomib, Pomalidomide, and Dexamethasone in Adults With Primary Refractory or Relapsed and Refractory Multiple Myeloma
Phase 1
Terminated
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 33
- Registration Number
- NCT01999335
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸James R. Berenson, MD, Inc., West Hollywood, California, United States
🇺🇸Innovative Clinical Research Institute, Whittier, California, United States
© Copyright 2025. All Rights Reserved by MedPath